Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 59
Filtrar
1.
Int J Cosmet Sci ; 43(5): 619-626, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34403541

RESUMEN

INTRODUCTION: We report on the in vitro and ex vivo effects of chiral (R)-10-hydroxystearic acid (10-HSA) compared with other mono-hydroxystearic acid regioisomers and stearic acid (SA) together with its benefit when combined with retinol. METHODS: Following treatment with hydroxystearic acids peroxisomal proliferator-activated receptor alpha (PPARα) activity was determined in a luciferase reporter gene assay, collagen type I was assessed in primary human dermal fibroblasts by immunohistochemistry, modification of the intracellular fibroblast collagen proteome was studied by mass-spectrometry-based proteomics and collagen type III was assessed by immunohistochemistry on human ex vivo skin. RESULTS: 10-HSA was the most effective PPARα agonist (15.7× induction; p < 0.001), followed by 9-HSA (10.1× induction) and then 12-HSA (4.9× induction) with 17-HSA (1.7× induction) being similar to the effects of stearic acid (1.8× induction). Collagen type I levels were increased in primary human fibroblasts by 2.12× and 1.56× for 10-HSA and 9-HSA, respectively, in vitro with the10-HSA being significant (p < 0.05), whereas 12-HSA and SA had no statistical effect over the untreated control. 10-HSA and 12-HSA modified the intracellular fibroblast collagen proteome slightly with significant increases in collagen alpha-1 (VI) and alpha-3 (VI) proteins but only 10-HSA increased levels of collagen alpha-2 (V), alpha-1 (III), alpha-1 (I) and alpha-2 (I) (all p < 0.05) with the increases being significantly different between 10-HSA and 12-HSA for collagen alpha-1 (I), collagen-3 (VI) and collagen alpha-2 (I) (p < 0.01). Collagen type III in ex vivo skin was increased +47% (p < 0.05) by 0.05% (1.7 mM) retinol, +70% (p < 0.01) by 0.01% (0.33 mM) 10-HSA and the combination increased levels by +240% (p < 0.01 for either ingredient). CONCLUSION: Chiral (R)-10-HSA has been shown to be superior to 9, 12 and 17-HSA as a PPARα agonist. Moreover, 10-HSA stimulated collagen synthesis in monolayer fibroblast culture as assessed by proteomics and immunohistochemically. Furthermore, we also show the synergistic effects of 10-HSA with retinol on collagen III synthesis in skin explants. These results further highlight the efficacy of 10-HSA as a cosmetically acceptable PPARα agonist and anti-ageing ingredient.


INTRODUCTION: Nous rapportons les effets in vitro et ex vivo de l'acide chiral (R)-10-hydroxystéarique (10-HSA) par rapport à d'autres régioisomères d'acide mono-hydroxystéarique et à l'acide stéarique (SA) ainsi que ses avantages lorsqu'il est associé au rétinol. MÉTHODES: Après un traitement avec des acides hydroxystéariques, l'activité du récepteur alpha activé par les proliférateurs peroxysomaux (PPARα) a été déterminée dans un test du gène rapporteur de la luciférase, le collagène de type I a été évalué dans les fibroblastes dermiques humains primaires par immunohistochimie, la modification du protéome du collagène des fibroblastes intracellulaires a été étudiée par spectrométrie de masse. La protéomique et le collagène de type III ont été évalués par immunohistochimie sur la peau humaine ex vivo. RÉSULTATS: la 10-HSA était l'agoniste PPARα le plus efficace (induction 15,7X ; p<0,001), suivi de la 9-HSA (induction 10,1X) puis de la 12-HSA (induction 4,9X) avec la 17-HSA (induction 1,7X) étant similaire aux effets de l'acide stéarique (induction 1,8X). Les niveaux de collagène de type I ont été augmentés dans les fibroblastes humains primaires de 2,12X et 1,56X pour la 10-HSA et la 9-HSA respectivement in vitro, la 10-HSA étant significative (p<0,05) : alors que la 12-HSA et la SA n'ont eu aucun effet statistique sur le témoin non traité. La 10-HSA et la 12-HSA ont légèrement modifié le protéome du collagène des fibroblastes intracellulaires avec des augmentations significatives des protéines de collagène alpha-1 (VI) et alpha-3 (VI), mais seule la 10-HSA a augmenté les niveaux de collagène alpha-2 (V), alpha -1 (III), alpha-1 (I) et alpha-2 (I) (tous p<0,05) avec des augmentations significativement différentes entre 10-HSA et 12-HSA pour le collagène alpha-1 (I), le collagène- 3 (VI) et Collagène alpha-2 (I) (p<0,01). Le collagène de type III dans la peau ex vivo a augmenté de +47 % (p<0,05) de 0,05 % (1,7 mM) de rétinol, de +70 % (p<0,01) de 0,01 % (0,33 mM) de 10-HSA et la combinaison a augmenté les niveaux de +240 % (p<0,01 pour chaque ingrédient). CONCLUSION: La chiral (R)-10-HSA s'est avérée supérieure à 9, 12 et 17-HSA en tant qu'agoniste de PPARα. De plus, la 10-HSA a stimulé la synthèse de collagène dans la culture de fibroblastes monocouche telle qu'évaluée par protéomique et immunohistochimique. De plus, nous montrons également les effets synergiques de la 10-HSA avec le rétinol sur la synthèse du collagène III dans les explants de peau. Ces résultats soulignent en outre l'efficacité de la 10-HSA en tant qu'agoniste de PPARα et ingrédient anti-âge cosmétiquement acceptable.


Asunto(s)
Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo I/efectos de los fármacos , PPAR alfa/farmacología , Retinoides/farmacología , Envejecimiento de la Piel/efectos de los fármacos , Ácidos Esteáricos/farmacología , Sinergismo Farmacológico , Femenino , Fibroblastos/efectos de los fármacos , Células HEK293 , Humanos
2.
Endocr J ; 68(3): 307-315, 2021 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-33115984

RESUMEN

Testosterone deficiency is associated with poor prognosis among patients with chronic heart failure (HF). Physiological testosterone improves the exercise capacity of patients with HF. In this study, we evaluated whether treatment with physiological testosterone contributes to anti-fibrogenesis by modifying calcium homeostasis in cardiac fibroblasts and we studied the underlying mechanisms. Nitric oxide (NO) analyses, calcium (Ca2+) fluorescence, and Western blotting were performed in primary isolated rat cardiac fibroblasts with or without (control cells) testosterone (10, 100, 1,000 nmol/L) treatment for 48 hours. Physiological testosterone (10 nmol/L) increased NO production and phosphorylation at the inhibitory site of the inositol trisphosphate (IP3) receptor, thereby reducing Ca2+ entry, phosphorylated Ca2+/calmodulin-dependent protein kinase II (CaMKII) expression, type I and type III pro-collagen production. Non-physiological testosterone-treated fibroblasts exhibited similar NO and collagen production capabilities as compared to control (testosterone deficient) fibroblasts. These effects were blocked by co-treatment with NO inhibitor (L-NG-nitro arginine methyl ester [L-NAME], 100 µmol/L). In the presence of the IP3 receptor inhibitor (2-aminoethyl diphenylborinate [2-APB], 50 µmol/L), testosterone-deficient and physiological testosterone-treated fibroblasts exhibited similar phosphorylated CaMKII expression. When treated with 2-APB or CaMKII inhibitor (KN93, 10 µmol/L), testosterone-deficient and physiological testosterone-treated fibroblasts exhibited similar type I, and type III collagen production. In conclusion, physiological testosterone activates NO production, and attenuates the IP3 receptor/Ca2+ entry/CaMKII signaling pathway, thereby inhibiting the collagen production capability of cardiac fibroblasts.


Asunto(s)
Andrógenos/farmacología , Calcio/metabolismo , Fibroblastos/efectos de los fármacos , Óxido Nítrico/metabolismo , Testosterona/farmacología , Andrógenos/fisiología , Animales , Western Blotting , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/efectos de los fármacos , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/metabolismo , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/metabolismo , Fibroblastos/metabolismo , Fibrosis , Receptores de Inositol 1,4,5-Trifosfato/efectos de los fármacos , Receptores de Inositol 1,4,5-Trifosfato/metabolismo , Masculino , Miocardio/citología , Ratas , Testosterona/fisiología
3.
Acta Cir Bras ; 35(3): e202000303, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32490900

RESUMEN

PURPOSE: To evaluate the in vivo response of photobiomodulation therapy associated with norbixin-based poly(hydroxybutyrate) membrane (PHB) in tenotomized calcaneal tendon. METHODS: Thirty rats were randomly allocated to six groups (n=5 each): LED groups (L1, L2 and L3) and membrane + LED groups (ML1, ML2 and ML3). The right calcaneal tendons of all animals were sectioned transversely and were irradiated with LED daily, one hour after surgery every 24 hours, until the day of euthanasia. At the end of the experiments the tendons were removed for histological analysis. RESULTS: The histological analysis showed a significant reduction in inflammatory cells in the ML1, ML2 and ML3 groups (p=0.0056, p=0.0018 and p<0.0001, respectively) compared to those in the LED group. There was greater proliferation of fibroblasts in the ML1 (p<0.0001) and L3 (p<0.0001) groups. A higher concentration of type I collagen was also observed in the ML1 group (p=0.0043) replacing type III collagen. CONCLUSION: Photobiomodulation in association with norbixin-based PHB membrane led to control of the inflammatory process. However, it did not favor fibroblast proliferation and did not optimize type I collagen formation in the expected stage of the repair process.


Asunto(s)
Tendón Calcáneo/efectos de la radiación , Carotenoides/farmacología , Hidroxibutiratos/farmacología , Terapia por Luz de Baja Intensidad/métodos , Tendinopatía/radioterapia , Tenotomía/métodos , Tendón Calcáneo/efectos de los fármacos , Tendón Calcáneo/cirugía , Animales , Colágeno/farmacología , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Fibroblastos/química , Fibroblastos/efectos de los fármacos , Masculino , Prohibitinas , Distribución Aleatoria , Ratas , Ratas Wistar , Cicatrización de Heridas/efectos de los fármacos , Cicatrización de Heridas/efectos de la radiación
4.
Wound Repair Regen ; 28(4): 460-469, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32428986

RESUMEN

Hypertrophic scar is an important clinical problem with limited therapeutic options. Aside from their roles as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, statins have also been demonstrated to decrease scarring by reducing connective tissue growth factor (CTGF) expression. However, poor penetrative ability limits their utility as topical treatments for hypertrophic scar. Here, we aim to develop novel statin formulations using liposomes to enhance dermal penetrative ability and to evaluate their efficacy against formation of hypertrophic scar utilizing our validated rabbit ear hypertrophic scar model. Liposomal simvastatin or pravastatin were compounded using a novel, flexible liposomal formulation and applied topically to rabbit ear hypertrophic scars daily from postoperation day (POD) 14 until POD 25. Scar color, including erythema and melanin, was measured using reflectance spectrophotometry on POD 28, and scar tissue was harvested for evaluation of scar elevation index as well as gene and protein expression. Human foreskin fibroblasts were also treated with statin formulations and CCN2 expression was determined by quantitative PCR. Both simvastatin and pravastatin were efficiently encapsulated in liposomes, forming nanometer-scale particles possessing highly negative charges. Topical treatment with liposomal simvastatin and pravastatin at 6.5% concentration significantly reduced scar elevation index and decreased type I/III collagen content and myofibroblast persistence in the wound. The erythema/vascularity of scars was reduced by liposomal statin treatment, with concomitant decrease of CD31 expression as measured histologically. Expression levels of transcripts encoding CTGF, collagen I, and collagen III collagen in scar tissue were also decreased by liposomal pravastatin treatment, as were myofibroblast persistence and the type I/III collagen ratio as assessed by immunofluorescence and picrosirus red staining, respectively. Treatment of human foreskin fibroblasts with simvastatin or with liposome-encapsulated pravastatin resulted in decreased expression of transcript encoding CTGF. Overall, our novel statin formulations encapsulated in liposomes were successfully delivered through topical application, significantly reducing hypertrophic scarring in a rabbit ear model.


Asunto(s)
Cicatriz Hipertrófica/metabolismo , Fibroblastos/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Piel/metabolismo , Animales , Cicatriz Hipertrófica/patología , Cicatriz Hipertrófica/prevención & control , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/genética , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/genética , Factor de Crecimiento del Tejido Conjuntivo/efectos de los fármacos , Factor de Crecimiento del Tejido Conjuntivo/genética , Oído Externo/lesiones , Oído Externo/metabolismo , Oído Externo/patología , Eritema , Fibroblastos/metabolismo , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Técnicas In Vitro , Liposomas , Melaninas , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/efectos de los fármacos , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Pravastatina/administración & dosificación , Pravastatina/farmacología , Conejos , Simvastatina/administración & dosificación , Simvastatina/farmacología , Piel/lesiones , Piel/patología , Espectrofotometría
5.
Acta Cir Bras ; 34(11): e201901101, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31939594

RESUMEN

PURPOSE: To determine the efficacy of norbixin-based poly(hydroxybutyrate) (PHB) membranes for Achilles tendon repair. METHODS: Thirty rats were submitted to total tenotomy surgery of the right Achilles tendon and divided into two groups (control and membrane; n = 15 each), which were further subdivided into three subgroups (days 7, 14, and 21; n = 5 each). Samples were analyzed histologically. RESULTS: Histological analysis showed a significant reduction in inflammatory infiltrates on days 7, 14 (p < 0.0001 for both), and 21 (p = 0.0004) in the membrane group compared to that in the control group. There was also a significant decrease in the number of fibroblasts in the control group on days 7, 14 (p < 0.0001), and 21 (p = 0.0032). Further, an increase in type I collagen deposition was observed in the membrane group compared to that in the control group on days 7 (p = 0.0133) and 14 (p = 0.0107). CONCLUSION: Treatment with norbixin-based PHB membranes reduces the inflammatory response, increases fibroblast proliferation, and improves collagen production in the tendon repair region, especially between days 7 and 14.


Asunto(s)
Tendón Calcáneo/efectos de los fármacos , Tendón Calcáneo/cirugía , Carotenoides/farmacología , Hidroxibutiratos/farmacología , Poliésteres/farmacología , Tenotomía/métodos , Tendón Calcáneo/patología , Animales , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Humanos , Masculino , Prohibitinas , Ratas Wistar , Valores de Referencia , Regeneración/efectos de los fármacos , Reproducibilidad de los Resultados , Factores de Tiempo , Resultado del Tratamiento
6.
Wound Repair Regen ; 28(1): 39-48, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31587435

RESUMEN

To study the effects of mir-27b on angiogenesis and fibroblast activation and to explore its further mechanism. Humanmicrovascular endothelial cell (HMEC)-1 and humannormal skin fibroblast (BJ) cells were treated with mir-27b inhibitor negative control reagent, mir-27b inhibitor, LY294002, and mir-27b inhibitor + LY294002, respectively. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used to detect the T-cell proliferation. The migration ability was detected by Scratch assays. The angiogenesis of HMEC-1 cells was observed by in vitro tube formation assay. The mRNA and protein expression of vascular endothelial growth factor (VEGF) in HMEC-1 cells and the mRNA and protein expression of collagen I, collagen III, α-SMA, and MMP1 in BJ cells were detected by quantitativereal-time polymerase chain reaction (qRT-PCR) and Western blot, respectively. Meanwhile, the PI3K/protein kinase B (AKT) pathway-related proteins were also detected by Western blot. The proliferation, migration, angiogenesis, the mRNA and protein expression of VEGF and the protein expression of p-PI3K and p-AKT in HMEC-1 cells were increased after treated with mir-27b inhibitor. Meanwhile, the proliferation, migration, and the protein expression of collagen I, collagen III, α-SMA, MMP1, p-PI3K, and p-AKT in BJ cells were increased after treated with mir-27b inhibitor. However, the angiogenesis and fibroblast activation of mir-27b inhibitor was reversed by LY294002, and the activate effect to PI3K/AKT pathway was also inhibited. Down-regulation of mir-27b could promote angiogenesis and fibroblast activation, and its mechanism is related to activate PI3K/AKT signaling pathway.


Asunto(s)
Proliferación Celular/genética , Células Endoteliales/metabolismo , Fibroblastos/metabolismo , Neovascularización Fisiológica/genética , Fosfatidilinositol 3-Quinasas/genética , Proteínas Proto-Oncogénicas c-akt/genética , Actinas/efectos de los fármacos , Actinas/genética , Actinas/metabolismo , Movimiento Celular/efectos de los fármacos , Movimiento Celular/genética , Proliferación Celular/efectos de los fármacos , Cromonas/farmacología , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Regulación hacia Abajo , Células Endoteliales/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Humanos , Metaloproteinasa 1 de la Matriz/efectos de los fármacos , Metaloproteinasa 1 de la Matriz/genética , Metaloproteinasa 1 de la Matriz/metabolismo , MicroARNs/antagonistas & inhibidores , MicroARNs/genética , Morfolinas/farmacología , Neovascularización Fisiológica/efectos de los fármacos , Fosfatidilinositol 3-Quinasas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Transducción de Señal , Piel/citología , Factor A de Crecimiento Endotelial Vascular/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/metabolismo , Cicatrización de Heridas
7.
Acta cir. bras ; 35(3): e202000303, 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1130621

RESUMEN

Abstract Purpose: To evaluate the in vivo response of photobiomodulation therapy associated with norbixin-based poly(hydroxybutyrate) membrane (PHB) in tenotomized calcaneal tendon. Methods: Thirty rats were randomly allocated to six groups (n=5 each): LED groups (L1, L2 and L3) and membrane + LED groups (ML1, ML2 and ML3). The right calcaneal tendons of all animals were sectioned transversely and were irradiated with LED daily, one hour after surgery every 24 hours, until the day of euthanasia. At the end of the experiments the tendons were removed for histological analysis. Results: The histological analysis showed a significant reduction in inflammatory cells in the ML1, ML2 and ML3 groups (p=0.0056, p=0.0018 and p<0.0001, respectively) compared to those in the LED group. There was greater proliferation of fibroblasts in the ML1 (p<0.0001) and L3 (p<0.0001) groups. A higher concentration of type I collagen was also observed in the ML1 group (p=0.0043) replacing type III collagen. Conclusion: Photobiomodulation in association with norbixin-based PHB membrane led to control of the inflammatory process. However, it did not favor fibroblast proliferation and did not optimize type I collagen formation in the expected stage of the repair process.


Asunto(s)
Animales , Masculino , Ratas , Tendón Calcáneo/efectos de la radiación , Carotenoides/farmacología , Terapia por Luz de Baja Intensidad/métodos , Tendinopatía/radioterapia , Tenotomía/métodos , Hidroxibutiratos/farmacología , Tendón Calcáneo/cirugía , Tendón Calcáneo/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos , Cicatrización de Heridas/efectos de la radiación , Distribución Aleatoria , Colágeno/farmacología , Ratas Wistar , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Fibroblastos/efectos de los fármacos , Fibroblastos/química , Prohibitinas
8.
Acta cir. bras ; 34(11): e201901101, Nov. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1054681

RESUMEN

Abstract Purpose: To determine the efficacy of norbixin-based poly(hydroxybutyrate) (PHB) membranes for Achilles tendon repair. Methods: Thirty rats were submitted to total tenotomy surgery of the right Achilles tendon and divided into two groups (control and membrane; n = 15 each), which were further subdivided into three subgroups (days 7, 14, and 21; n = 5 each). Samples were analyzed histologically. Results: Histological analysis showed a significant reduction in inflammatory infiltrates on days 7, 14 (p < 0.0001 for both), and 21 (p = 0.0004) in the membrane group compared to that in the control group. There was also a significant decrease in the number of fibroblasts in the control group on days 7, 14 (p < 0.0001), and 21 (p = 0.0032). Further, an increase in type I collagen deposition was observed in the membrane group compared to that in the control group on days 7 (p = 0.0133) and 14 (p = 0.0107). Conclusion: Treatment with norbixin-based PHB membranes reduces the inflammatory response, increases fibroblast proliferation, and improves collagen production in the tendon repair region, especially between days 7 and 14.


Asunto(s)
Humanos , Animales , Masculino , Poliésteres/farmacología , Tendón Calcáneo/cirugía , Tendón Calcáneo/efectos de los fármacos , Carotenoides/farmacología , Tenotomía/métodos , Hidroxibutiratos/farmacología , Valores de Referencia , Regeneración/efectos de los fármacos , Tendón Calcáneo/patología , Reproducibilidad de los Resultados , Ratas Wistar , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Fibroblastos/efectos de los fármacos
9.
Osteoarthritis Cartilage ; 25(12): 1952-1961, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28964890

RESUMEN

OBJECTIVE: To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-981, a human dual variable domain immunoglobulin simultaneously targeting interleukin (IL)-1α and IL-1ß, in patients with knee osteoarthritis (OA). METHOD: This was a randomized, double-blind, placebo-controlled, single-center study of multiple subcutaneous (SC) injections of ABT-981 in patients with mild-to-moderate OA of the knee (NCT01668511). Three cohorts received ABT-981 (0.3, 1, or 3 mg/kg) or placebo every other week for a total of four SC injections, and one cohort received ABT-981 (3 mg/kg) or placebo every 4 weeks for a total of three SC injections. Assessment of safety and tolerability were the primary objectives. A panel of serum and urine biomarkers of inflammation and joint degradation were evaluated. RESULTS: A total of 36 patients were randomized (ABT-981, n = 28; placebo, n = 8); 31 (86%) completed the study. Adverse event (AE) rates were comparable between ABT-981 and placebo (54% vs 63%). The most common AE reported with ABT-981 vs placebo was injection site erythema (14% vs 0%). ABT-981 significantly reduced absolute neutrophil count and serum concentrations of IL-1α/IL-1ß, high-sensitivity C-reactive protein, and matrix metalloproteinase (MMP)-derived type 1 collagen. Serum concentrations of MMP-derived type 3 collagen and MMP-degraded C-reactive protein demonstrated decreasing trends with ABT-981. Antidrug antibodies were found in 37% of patients but were not associated with the incidence or severity of AEs. CONCLUSION: ABT-981 was generally well tolerated in patients with knee OA and engaged relevant tissue targets, eliciting an anti-inflammatory response. Consequently, ABT-981 may provide clinical benefit to patients with inflammation-driven OA.


Asunto(s)
Inmunoglobulinas/uso terapéutico , Interleucina-1alfa/antagonistas & inhibidores , Interleucina-1beta/antagonistas & inhibidores , Osteoartritis de la Rodilla/tratamiento farmacológico , Anciano , Agrecanos/efectos de los fármacos , Agrecanos/metabolismo , Proteína C-Reactiva/efectos de los fármacos , Proteína C-Reactiva/metabolismo , Proteína de la Matriz Oligomérica del Cartílago/efectos de los fármacos , Proteína de la Matriz Oligomérica del Cartílago/metabolismo , Citrulinación , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/metabolismo , Eritema , Femenino , Humanos , Inmunoglobulinas/farmacología , Reacción en el Punto de Inyección , Inyecciones Subcutáneas , Interleucina-1beta/efectos de los fármacos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Neutrófilos/citología , Osteoartritis de la Rodilla/metabolismo , Péptidos/efectos de los fármacos , Péptidos/metabolismo , Índice de Severidad de la Enfermedad , Factor A de Crecimiento Endotelial Vascular/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vimentina/efectos de los fármacos , Vimentina/metabolismo
10.
J Tissue Viability ; 26(2): 131-137, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28162862

RESUMEN

It has been reported that carbohydrates confer physicochemical properties to the wound environment that improves tissue repair. We evaluated in vitro and in vivo wound healing during maltodextrin/ascorbic acid treatment. In a fibroblast monolayer scratch assay, we demonstrated that maltodextrin/ascorbic acid stimulated monolayer repair by increasing collagen turnover coordinately with TGF-ß1 expression (rising TGF-ß1 and MMP-1 expression, as well as gelatinase activity, while TIMP-1 was diminished), similar to in vivo trends. On the other hand, we observed that venous leg ulcers treated with maltodextrin/ascorbic acid diminished microorganism population and improved wound repair during a 12 week period. When maltodextrin/ascorbic acid treatment was compared with zinc oxide, almost four fold wound closure was evidenced. Tissue architecture and granulation were improved after the carbohydrate treatment also, since patients that received maltodextrin/ascorbic acid showed lower type I collagen fiber levels and increased extracellular alkaline phosphatase activity and blood vessels than those treated with zinc oxide. We hypothesize that maltodextrin/ascorbic acid treatment stimulated tissue repair of chronic wounds by changing the stage of inflammation and modifying collagen turnover directly through fibroblast response.


Asunto(s)
Antioxidantes/administración & dosificación , Ácido Ascórbico/administración & dosificación , Polisacáridos/administración & dosificación , Úlcera Varicosa/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Administración Cutánea , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Colágeno Tipo III/efectos de los fármacos , Combinación de Medicamentos , Femenino , Humanos , Estudios Longitudinales , Extremidad Inferior , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Distribución Aleatoria , Inhibidor Tisular de Metaloproteinasa-1/efectos de los fármacos , Factor de Crecimiento Transformador beta1/efectos de los fármacos , Úlcera Varicosa/microbiología , Úlcera Varicosa/patología , Óxido de Zinc/administración & dosificación
11.
World J Urol ; 35(8): 1247-1254, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28013345

RESUMEN

OBJECTIVES: To investigate the effect of simulated physiological stretch on the expression of extracellular matrix (ECM) proteins and the role of integrin α4/αv, focal adhesion kinase (FAK), extracellular regulated protein kinases 1/2 (ERK1/2) in the stretch-induced ECM protein expression of human bladder smooth muscle cells (HBSMCs). METHODS: HBSMCs were seeded onto silicone membrane and subjected to simulated physiological stretch at the range of 5, 10, and 15% elongation. Expression of primary ECM proteins in HBSMCs was analyzed by real-time polymerase chain reaction and Western blot. Specificity of the FAK and ERK1/2 was determined by Western blot with FAK inhibitor and ERK1/2 inhibitor (PD98059). Specificity of integrin α4 and integrin αv was determined with small interfering ribonucleic acid (siRNA) transfection. RESULTS: The expression of collagen I (Col1), collagen III (Col3), and fibronectin (Fn) was increased significantly under the simulated physiological stretch of 10 and 15%. Integrin α4 and αv, FAK, ERK1/2 were activated by 10% simulated physiological stretch compared with the static condition. Pretreatment of ERK1/2 inhibitor, FAK inhibitor, integrin α4 siRNA, or integrin αv siRNA reduced the stretch-induced expression of ECM proteins. And FAK inhibitor decreased the stretch-induced ERK1/2 activity and ECM protein expression. Integrin α4 siRNA or integrin αv siRNA inhibited the stretch-induced activity of FAK. CONCLUSION: Simulated physiological stretch increases the expression of ECM proteins in HBSMCs, and integrin α4/αv-FAK-ERK1/2 signaling pathway partly modulates the mechano-transducing process.


Asunto(s)
Proteínas de la Matriz Extracelular/genética , Quinasa 1 de Adhesión Focal/genética , Integrina alfa4/genética , Integrina alfaV/genética , Sistema de Señalización de MAP Quinasas/genética , Miocitos del Músculo Liso/metabolismo , Fenómenos Biomecánicos , Western Blotting , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Proteínas de la Matriz Extracelular/efectos de los fármacos , Proteínas de la Matriz Extracelular/metabolismo , Fibronectinas/efectos de los fármacos , Fibronectinas/genética , Fibronectinas/metabolismo , Flavonoides/farmacología , Quinasa 1 de Adhesión Focal/efectos de los fármacos , Quinasa 1 de Adhesión Focal/metabolismo , Humanos , Integrina alfa4/efectos de los fármacos , Integrina alfa4/metabolismo , Integrina alfaV/efectos de los fármacos , Integrina alfaV/metabolismo , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Miocitos del Músculo Liso/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , ARN Interferente Pequeño/farmacología , Reacción en Cadena en Tiempo Real de la Polimerasa , Transducción de Señal , Vejiga Urinaria/citología
12.
Pesqui. vet. bras ; 36(12): 1221-1226, Dec. 2016. tab, ilus
Artículo en Inglés | LILACS, VETINDEX | ID: biblio-842029

RESUMEN

Collagen plays essential roles in remodeling uterine tissue during decidualization, implantation, pregnancy and involution. To understand whether the progestational agent medroxyprogesterone acetate (MPA) can modify the organization and deposit of collagen in the uteri of normal bitches (Canis Tlupus familiaris), we assessed uterine tissues by histochemistry. Uteri were grouped as: nulliparous (n=11), multiparous (n=11) and treated with MPA (n=11; nulliparous with two treatments; 5mg/kg; i.m.). The amount, location and birefringence of interstitial collagen types I and III in the fold and base of the endometrial stroma and the myometrial muscular layers were studied on sections stained with Picrosirius Red by polarized light microscopy and evaluated by ANOVA. No differences were observed in the endometrium. In the myometrium, differences were observed in collagen type I between MPA-treated and nulliparous uteri vs. multiparous (p<0.05), and differences in collagen type III between nulliparous and multiparous uteri vs. MPA-treated (p=0.0001). In conclusion, two doses of MPA had no significant effect on the investigated collagens in the extracellular matrix.(AU)


Asunto(s)
Animales , Femenino , Perros , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo I/efectos de los fármacos , Acetato de Medroxiprogesterona/efectos adversos , Útero/anatomía & histología , Anticonceptivos/análisis , Colágenos Fibrilares
13.
Surg Endosc ; 30(5): 2016-21, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26264696

RESUMEN

BACKGROUND: Ventral hernia is a commonly occurring surgical problem. Our earlier studies have shown that a 30 mg/kg dose of doxycycline can significantly impact the strength of polypropylene (PP) mesh in a rat hernia repair model at 6 and 12 weeks. The objective of the present study was to investigate the dose dependence of doxycycline treatment on hernia repair strengths in rats. STUDY DESIGN: Fifty-six Sprague-Dawley rats underwent hernia repair with either PP mesh (n = 28) or sutures only (primary; n = 28); both groups were further divided into four doxycycline groups of seven animals each: control (0 mg/kg), low (3 mg/kg), medium (10 mg/kg), and high (30 mg/kg). One day before hernia repair surgery, animals received doxycycline doses by gavage and continued receiving daily until euthanasia. After 8 weeks, rats were euthanized and tissue samples from hernia repaired area were collected and analyzed for tensile strength using a tensiometer (Instron, Canton, MA, USA), while MMPs 2, 3, and 9, and collagen type 1 and 3 were analyzed by western blotting. RESULTS: In mesh-repaired animals, medium and high doxycycline dose repaired mesh fascia interface (MFI) showed significant increase in tensile strength when compared to control. In the primary repaired animals, there was no significant difference in MFI tensile strength in any dose group. In medium-dose MFI, there was a significant reduction in MMPs 2, 3, and 9. In this animal group, MFI showed significant increase in collagen 1 and significant reduction in collagen type 3 when compared to control. CONCLUSION: It is possible to improve the strength of mesh-repaired tissue by administering a significantly lower dose of the drug, which has implications for translation of the findings.


Asunto(s)
Antibacterianos/farmacología , Doxiciclina/farmacología , Fascia/efectos de los fármacos , Hernia Ventral/cirugía , Herniorrafia/métodos , Mallas Quirúrgicas , Resistencia a la Tracción/efectos de los fármacos , Animales , Western Blotting , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/metabolismo , Relación Dosis-Respuesta a Droga , Fascia/metabolismo , Masculino , Metaloproteinasa 2 de la Matriz/efectos de los fármacos , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/efectos de los fármacos , Metaloproteinasa 9 de la Matriz/metabolismo , Polipropilenos , Prótesis e Implantes , Ratas , Ratas Sprague-Dawley , Suturas
14.
Int J Low Extrem Wounds ; 14(4): 343-52, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26315898

RESUMEN

The purpose of this article is to investigate the effect of Opuntia stricta H (Cactaceae) extract on suppression of hypertrophic scar on ventral surface wounds of rabbit ears. Full thickness skin defection was established in a rabbit ear to simulate hypertrophic scar. Opuntia extract was sprayed on the wounds in the experimental group, and normal saline was used in the control group. After the wounds healed with scar formation, the hypertrophic scar tissue was harvested on days 22, 39, and 54 for histological analysis. The expression of type I and type III collagen and matrix metalloproteinase-1 (MMP-1) were evaluated by immunohistochemistry and real-time quantitative polymerase chain reaction. The results indicated that the scar of the control group is more prominent compared with the opuntia extract group. The expression of type I collagen in the opuntia extract group was lower than the control group, while type III collagen in opuntia extract group gradually increased and exceeded control group. The expression of MMP-1 decreased in the opuntia extract group, while the control group increased over time, but the amount of MMP-1 was much higher than that in the control group on day 22. In conclusion, opuntia extract reduces hypertrophic scar formation by means of type I collagen inhibition, and increasing type III collagen and MMP-1.T he novel application of opuntia extract may lead to innovative and effective antiscarring therapies.


Asunto(s)
Cicatriz Hipertrófica/prevención & control , Opuntia , Fitoterapia , Extractos Vegetales/uso terapéutico , Animales , Cicatriz Hipertrófica/metabolismo , Colágeno Tipo I/biosíntesis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/biosíntesis , Colágeno Tipo III/efectos de los fármacos , Modelos Animales de Enfermedad , Oído , Masculino , Metaloproteinasa 1 de la Matriz/biosíntesis , Metaloproteinasa 1 de la Matriz/efectos de los fármacos , Conejos , Distribución Aleatoria
15.
J Shoulder Elbow Surg ; 24(7): e175-84, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25825137

RESUMEN

BACKGROUND: To improve the success rate of rotator cuff repair, we investigated whether octacalcium phosphate (OCP) with gelatin (Gel) vehicle had a positive effect on tendon-to-bone healing. METHODS: We assessed the histologic characteristics of the tendon-to-bone healing using the rabbit rotator cuff repair model. We divided the shoulders into 3 groups: control (without OCP/Gel composite), OCP/Gel composite (OCP+group), and Gel alone without OCP (Gel group) to evaluate the effectiveness of gelatin. RESULTS: Both the number of newly formed tendon fibers and the Sharpey fibers at the repair site increased in the OCP+group compared with those in the other 2 groups on hematoxylin-eosin staining (P < .05). On immunohistochemical evaluation, both the bone and the fibers in the OCP+group demonstrated that type I collagen was picked up, whereas the newly formed tendon fibers and Sharpey fibers revealed type III collagen. CONCLUSION: Treatment with OCP made collagen fibers and the Sharpey fibers, constituted by type I and type III collagens, increase at the tendon-to-bone insertion. It might be beneficial for the healing of rotator cuff tendon to bone.


Asunto(s)
Sustitutos de Huesos/farmacología , Fosfatos de Calcio/farmacología , Osteogénesis/efectos de los fármacos , Regeneración/efectos de los fármacos , Manguito de los Rotadores/cirugía , Animales , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/fisiología , Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/fisiología , Modelos Animales , Conejos , Tendones/fisiología
16.
Acta Cir Bras ; 30(1): 24-33, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25627268

RESUMEN

PURPOSE: To evaluate the effect of propranolol on capsular architecture around silicone implants by measuring the inflammation, capsular thickness, and collagen fiber density, using a guinea pig experimental model. METHODS: Thirty six adult male guinea pigs randomly divided into two groups (n=18) were used. Each one received a silicone implant with textured-surface. The capsular tissue around implants from untreated or treated animals with the beta-adrenoceptor antagonist propranolol (10 mg/kg, dissolved in daily water) were analyzed for inflammation by histological scoring, capsular thickness by computerized histometry, and collagen fibers type I and Type III density by picrosirius polarization at different time points (7, 14 or 21 days after silicone implantation). RESULTS: Propranolol treatment reduced inflammation and impaired capsular thickness and delayed collagen maturation around the textured implant. CONCLUSION: Propranolol reduces the risk of developing capsular contracture around silicone implants with textured surface.


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Contractura Capsular en Implantes/prevención & control , Propranolol/farmacología , Geles de Silicona/efectos adversos , Antagonistas Adrenérgicos beta/uso terapéutico , Animales , Implantes de Mama/efectos adversos , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Modelos Animales de Enfermedad , Cobayas , Humanos , Contractura Capsular en Implantes/patología , Implantes Experimentales/efectos adversos , Masculino , Propranolol/uso terapéutico , Distribución Aleatoria , Reproducibilidad de los Resultados , Tejido Subcutáneo/efectos de los fármacos , Tejido Subcutáneo/patología , Factores de Tiempo , Resultado del Tratamiento
17.
Acta cir. bras ; 30(1): 24-33, 01/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-735711

RESUMEN

PURPOSE: To evaluate the effect of propranolol on capsular architecture around silicone implants by measuring the inflammation, capsular thickness, and collagen fiber density, using a guinea pig experimental model. METHODS: Thirty six adult male guinea pigs randomly divided into two groups (n=18) were used. Each one received a silicone implant with textured-surface. The capsular tissue around implants from untreated or treated animals with the beta-adrenoceptor antagonist propranolol (10 mg/kg, dissolved in daily water) were analyzed for inflammation by histological scoring, capsular thickness by computerized histometry, and collagen fibers type I and Type III density by picrosirius polarization at different time points (7, 14 or 21 days after silicone implantation). RESULTS: Propranolol treatment reduced inflammation and impaired capsular thickness and delayed collagen maturation around the textured implant. CONCLUSION: Propranolol reduces the risk of developing capsular contracture around silicone implants with textured surface. .


Asunto(s)
Animales , Cobayas , Humanos , Masculino , Antagonistas Adrenérgicos beta/farmacología , Contractura Capsular en Implantes/prevención & control , Propranolol/farmacología , Geles de Silicona/efectos adversos , Antagonistas Adrenérgicos beta/uso terapéutico , Implantes de Mama/efectos adversos , Colágeno Tipo I/análisis , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/análisis , Colágeno Tipo III/efectos de los fármacos , Modelos Animales de Enfermedad , Contractura Capsular en Implantes/patología , Implantes Experimentales/efectos adversos , Propranolol/uso terapéutico , Distribución Aleatoria , Reproducibilidad de los Resultados , Tejido Subcutáneo/efectos de los fármacos , Tejido Subcutáneo/patología , Factores de Tiempo , Resultado del Tratamiento
18.
Wound Repair Regen ; 22(4): 521-6, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25041621

RESUMEN

Age-related changes in the extracellular matrix contribute to delayed wound repair in aging. Hyaluronan, a linear nonsulfated glycosaminoglycan, promotes synthesis and assembly of key extracellular matrix components, such as the interstitial collagens, during wound healing. The biological effects of hyaluronan are mediated, in part, by hyaluronan size. We have previously determined that dermal wounds in aged mice, relative to young mice, have deficits in the generation of lower molecular weight hyaluronan (defined as <300 kDa). Here, we tested the effect of exogenous hyaluronan of 2, 250, or 1,000 kDa sizes on full-thickness excisional wounds in aged mice. Only wounds treated with 250 kDa hyaluronan (HA250) were significantly improved over wounds that received carrier (water) alone. Treatment with HA250 was associated with increased expression of transcripts for the hyaluronan receptors CD44 and RHAMM, as well as collagens III and I. Analyses of dermal protein content by mass spectrometry and Western blotting confirmed significantly increased expression of collagen III in wounds treated with HA250 relative to control wounds. In summary, we find that HA250 improves wound repair and increases the synthesis of collagen III in aged dermal wounds.


Asunto(s)
Colágeno Tipo III/efectos de los fármacos , Colágeno Tipo III/metabolismo , Ácido Hialurónico/farmacología , Traumatismos de los Tejidos Blandos/metabolismo , Cicatrización de Heridas/efectos de los fármacos , Envejecimiento/metabolismo , Animales , Western Blotting , Dermis/metabolismo , Matriz Extracelular/metabolismo , Proteínas de la Matriz Extracelular/metabolismo , Receptores de Hialuranos/efectos de los fármacos , Receptores de Hialuranos/metabolismo , Ácido Hialurónico/metabolismo , Masculino , Espectrometría de Masas , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/metabolismo , Traumatismos de los Tejidos Blandos/tratamiento farmacológico
19.
Int Braz J Urol ; 40(2): 257-63, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24856494

RESUMEN

PURPOSE: To evaluate the synthesis of type I (mature) and type III (immature) collagen in bladder suture of rats treated with a combination of tacrolimus and mycophenolate mofetil for 15 days. MATERIALS AND METHODS: Thirty rats were divided into 3 groups: the sham, control and experimental groups. All the animals underwent laparotomy, cystotomy and bladder suture in two planes with surgical PDS 5-0 thread. The sham group did not receive treatment. The control group received saline solution, and the experimental group received 0.1mg/kg/day of tacrolimus with 20mg/kg/day of mycophenolate mofetil, for 15 days. From then on, the tacrolimus was dosed. The surgical specimens of the bladder suture area were processed so that the total type I and type III collagen could be measured by the picrosirius red technique. RESULTS: There was a predominance of type I collagen production in the sham and control groups compared to the experimental group, in which type III collagen was predominant. The production of total collagen did not change. CONCLUSION: The association of tacrolimus and mycophenolate mofetil in animals qualitatively changes the production of collagen after 15 days with a predominance of type III collagen.


Asunto(s)
Colágeno Tipo III/biosíntesis , Colágeno Tipo I/biosíntesis , Inmunosupresores/uso terapéutico , Ácido Micofenólico/análogos & derivados , Suturas , Tacrolimus/uso terapéutico , Vejiga Urinaria/cirugía , Animales , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/efectos de los fármacos , Ácido Micofenólico/uso terapéutico , Ratas Wistar , Reproducibilidad de los Resultados , Técnicas de Sutura , Resultado del Tratamiento , Cicatrización de Heridas/efectos de los fármacos
20.
Int. braz. j. urol ; 40(2): 257-265, Mar-Apr/2014. graf
Artículo en Inglés | LILACS | ID: lil-711695

RESUMEN

PurposeTo evaluate the synthesis of type I (mature) and type III (immature) collagen in bladder suture of rats treated with a combination of tacrolimus and mycophenolate mofetil for 15 days.Materials and MethodsThirty rats were divided into 3 groups: the sham, control and experimental groups. All the animals underwent laparotomy, cystotomy and bladder suture in two planes with surgical PDS 5-0 thread. The sham group did not receive treatment. The control group received saline solution, and the experimental group received 0.1mg/kg/day of tacrolimus with 20mg/kg/day of mycophenolate mofetil, for 15 days. From then on, the tacrolimus was dosed. The surgical specimens of the bladder suture area were processed so that the total type I and type III collagen could be measured by the picrosirius red technique.ResultsThere was a predominance of type I collagen production in the sham and control groups compared to the experimental group, in which type III collagen was predominant. The production of total collagen did not change.ConclusionThe association of tacrolimus and mycophenolate mofetil in animals qualitatively changes the production of collagen after 15 days with a predominance of type III collagen.


Asunto(s)
Animales , Colágeno Tipo I/biosíntesis , Colágeno Tipo III/biosíntesis , Inmunosupresores/uso terapéutico , Ácido Micofenólico/análogos & derivados , Suturas , Tacrolimus/uso terapéutico , Vejiga Urinaria/cirugía , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo III/efectos de los fármacos , Ácido Micofenólico/uso terapéutico , Ratas Wistar , Reproducibilidad de los Resultados , Técnicas de Sutura , Resultado del Tratamiento , Cicatrización de Heridas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA